Product image of Meliglix 100 Mg (Sitagliptin Hydrochloride) supplied by GNH India

Meliglix 100 Mg

Active Ingredient:
Sitagliptin Hydrochloride
Origin:
EU

Meliglix 100 Mg (Sitagliptin Hydrochloride)

Sitagliptin Hydrochloride, the active ingredient in Meliglix 100 Mg, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as a 100 mg tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used as part of a comprehensive diabetes treatment plan.

GNH India supplies Meliglix 100 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory conformity across markets and providing reliable logistics support for timely delivery.

Manufacturer / TM Owner

Pharmazac Sa

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Meliglix (sitagliptin) is used to improve glycaemic control in the type 2 diabetes therapeutic pathway.

  • Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels.
  • Monotherapy in patients unsuitable for metformin: provides effective glucose reduction as a single oral agent.
  • Combination therapy with other antidiabetics: enhances overall glycaemic control when added to agents such as sulfonylureas or insulin.

How It Works

  • Sitagliptin Hydrochloride selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which degrades the incretin hormones GLP‑1 and GIP. By preventing this degradation, endogenous GLP‑1 and GIP concentrations increase, leading to glucose‑dependent stimulation of insulin secretion and suppression of glucagon release, thereby reducing blood glucose concentrations.

Side Effects

Sitagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects

  • Nasopharyngitis: mild inflammation of the nasal passages and throat.
  • Headache: transient, mild to moderate intensity.
  • Upper respiratory tract infection: symptoms of cough, sore throat, or congestion.
  • Nausea: occasional mild gastrointestinal upset.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe allergic reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Joint pain: unexplained arthralgia that may be persistent.

Precautions & Warnings

When prescribing or dispensing Meliglix, consider the following safety measures.

  • Renal impairment: assess kidney function and adjust dose if necessary.
  • Hepatic impairment: monitor liver enzymes regularly.
  • History of pancreatitis: avoid use or discontinue promptly if symptoms recur.
  • Concomitant insulin or sulfonylureas: monitor for hypoglycaemia.
  • Pregnancy and lactation: safety not established; use only if benefits outweigh risks.
  • Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Sitagliptin may interact with other medicines; awareness of the interaction level is essential.

Major Interactions (Avoid)

  • Duplicate DPP‑4 inhibition: concurrent use with another DPP‑4 inhibitor can lead to excessive drug exposure.
  • Strong CYP3A4 inhibitors: may increase sitagliptin plasma levels, requiring caution.

Moderate Interactions (Monitor Closely)

  • Insulin or sulfonylureas: increased risk of hypoglycaemia, necessitating dose adjustments.
  • Diuretics causing dehydration: may affect renal clearance of sitagliptin.
  • Rifampin: may reduce sitagliptin effectiveness by inducing metabolism.

Frequently Asked Questions

Meliglix 100 Mg contains sitagliptin hydrochloride, a DPP‑4 inhibitor indicated for the treatment of type 2 diabetes mellitus in adults. It is used to improve glycaemic control when combined with diet, exercise, and other antidiabetic therapies as prescribed by a healthcare professional.

Sitagliptin hydrochloride blocks the enzyme dipeptidyl peptidase‑4, which normally breaks down the incretin hormones GLP‑1 and GIP. By preserving these hormones, the drug enhances glucose‑dependent insulin secretion and reduces glucagon release, leading to lower blood glucose levels.

The prescribed dose of Meliglix 100 Mg is determined by the treating physician based on individual patient factors such as renal function, glycaemic targets, and concomitant medications. Patients should follow the dosing instructions provided by their healthcare provider.

Safety of sitagliptin during pregnancy or lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by the prescribing clinician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Meliglix (sitagliptin) belongs to the DPP‑4 inhibitor class, which differs from sulfonylureas, metformin, or insulin. DPP‑4 inhibitors provide glucose‑dependent insulin release with a low risk of hypoglycaemia and are often used when metformin alone is insufficient or contraindicated.

Meliglix 100 Mg tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from excess moisture, heat, and direct sunlight to maintain product stability.

Meliglix 100 Mg is taken orally, usually once daily, with or without food, as directed by the prescribing physician. The tablet should be swallowed whole with water and not chewed or crushed.

Serious risks include pancreatitis, severe allergic reactions such as Stevens‑Johnson syndrome, and rare cases of hepatic injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or signs of liver dysfunction.

Meliglix should be avoided in patients with a known hypersensitivity to sitagliptin or any component of the formulation, and in those with a history of pancreatitis. Caution is also advised for individuals with severe renal impairment unless dose adjustments are made.

Medically reviewed by

Dr. Shweta Ashok More

M.Pharm (Quality Assurance), Ph.D. (Medicinal Chemistry), GNH India Pharmaceuticals Limited · Reviewed 9 Sep 2026

Published by GNH India Pharmaceuticals Limited · Last updated

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sitagliptin Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT